阿尔茨海默病脂酶D3的晶体结构为了解其正常和病理功能提供了分子基础
Kenta Ishii1,2, Stefan J Hermans1,2, Maria Eleni Georgopoulou1,2,3
1Structural Biology Laboratory, St Vincent's Institute of Medical Research, Fitzroy, Australia.
The FEBS journal
|September 26, 2024
概括
人类的酶PLD3,阿尔茨海默病的目标,作为核酶,而不是脂酶. 它的结构揭示了对阿尔茨海默病相关遗传变异的洞察力.
科学领域:
- 生物化学 生物化学
- 结构生物学 结构生物学
- 神经科学是一个神经科学.
背景情况:
- 脂酶D家族成员PLD3是阿尔茨海默病的治疗点.
- 了解PLD3的结构和功能对于开发阿尔茨海默氏症治疗非常重要.
研究的目的:
- 确定人类PLD3光域的晶体结构.
- 研究PLD3的酶活性,并将其催化残留与其他脂酶D酶进行比较.
- 分析单核酸多态 (SNP) 对PLD3结构和阿尔茨海默病的影响.
主要方法:
- 进行X射线晶体学以确定PLD3光域的2.3 Å分辨率结构.
- 生物化学测试以评估脂酶和核酶活性.
- 与其他人类PLD家族成员的结构比较.
- 将与疾病相关的SNP映射到确定结构上.
主要成果:
- PLD3光域表现出具有催化位点的双球结构.
- PLD3缺乏其他PLD家族成员中发现的保存的脂酶催化残留物.
- 没有检测到脂酶活性;观察到强大的核酶活性.
- 将SNP映射到结构上,为它们与阿尔茨海默病的关联提供了潜在的解释.
结论:
- 人类PLD3作为核酶起作用,挑战其在脂酶D家族中的分类.
- 确定的结构为了解PLD3在阿尔茨海默氏症病原发生中的作用提供了基础.
- 对PLD3的结构洞察力可能引导开发阿尔茨海默病的新疗法策略.
相关概念视频
Amyloid Fibrils
9.3K
Amyloid fibrils are aggregates of misfolded proteins. Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils.
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
9.3K
Alzheimer's Disease: Overview
451
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
451
Alzheimer's Disease: Treatment
170
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
170


